Health Technology · Pharmaceuticals: Major · NSE: BIOCON · data 2026-10-09
Biocon Limited
Health check: Weak (3.7/10 on quality, valuation vs sector, growth and momentum).
Open full analysis — chart, results, balance sheet, red flags →Key figures
Price
₹349.4
Market cap
₹56,821 cr
P/E
103.9
P/B
1.6
ROE
1.4%
ROCE
3.5%
Debt / equity
0.45
Dividend yield
0.14%
1-year return
-0.4%
52-week high
₹447.15
52-week low
₹337.7
Operating margin
8.6%
Growth
| Revenue (last 12 months) | ₹17,321 cr |
| Net profit (last 12 months) | ₹495 cr |
| Sales growth, 3 years (yearly) | 15.2% |
| Profit growth, 3 years (yearly) | -5.9% |
Similar companies
Alkem Laboratories Ltd. (ALKEM) · Glenmark Pharmaceuticals Limited (GLENMARK) · Abbott India Limited (ABBOTINDIA) · Gland Pharma Ltd. (GLAND) · IPCA Laboratories Limited (IPCALAB)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open BIOCON in NSE Scanner →